Affymax (AFFY) 0.0928 $AFFY
Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:14AM CST
Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.
ALNY: 121.77 (+5.73), GILD: 113.74 (+0.38), ABBV: 69.23 (+1.26)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 74.70 (-0.05), RIGL: 3.11 (+0.10)
Affymax up on dividend play
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 10:01AM CST
Affymax reports special cash distribution and new appointment
M2 - Fri Nov 28, 3:01AM CST
The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.
Affymax declares cash distribution, names new chief
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:29PM CST
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
Business Wire - Wed Nov 26, 3:20PM CST
Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code.
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer
Business Wire - Wed Nov 26, 3:15PM CST
Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014. The Board has also appointed Jonathan M. Couchman as a Class I director of the Company and as its President and Chief Executive Officer, and the remaining members of the Board have resigned. The Company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives.
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY
GlobeNewswire - Wed Nov 26, 3:59AM CST
TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX"
COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD" .
Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014 Special Meeting of Shareholders
PR Newswire - Fri Sep 19, 8:15AM CDT
Xstelos Holdings, Inc. and the members of its Schedule 13D group (collectively, the "Xstelos Group" or "we" own approximately 5.0% of the outstanding shares of common stock of Affymax, Inc. (OTC: AFFY) ("Affymax" or the "Company" . Today, the Xstelos Group announced its intention to vote its shares against Affymax's proposed plan of liquidation at the September 23, 2014 Special Meeting of Shareholders.
Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), XLRN: 30.03 (+0.20)
Affymax Reports Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:05PM CDT
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share) for the second quarter of 2013.
Gilead Tops Q4 Earnings Estimates, 2015 Outlook Disappoints - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 7:14AM CST
Gilead Sciences, Inc.'s (GILD) fourth-quarter earnings (including stock-based compensation expenses) of $2.38 per share.
ALNY: 121.77 (+5.73), GILD: 113.74 (+0.38), ABBV: 69.23 (+1.26)
KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors
GlobeNewswire - Mon Jan 05, 3:39PM CST
KYTHERA Biopharmaceuticals, Inc. (Nasdaq:KYTH) today announced that it has named Hollings C. Renton to its Board of Directors.
KYTH: 74.70 (-0.05), RIGL: 3.11 (+0.10)
Affymax up on dividend play
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 10:01AM CST
Affymax reports special cash distribution and new appointment
M2 - Fri Nov 28, 3:01AM CST
The board of directors of Affymax (Other OTC:AFFY), a biopharmaceutical company, on Thursday declared its special distribution of USD0.05 per share of its stock.
Affymax declares cash distribution, names new chief
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:29PM CST
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss Carryforwards
Business Wire - Wed Nov 26, 3:20PM CST
Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss carryforwards, or NOLs, in relation to the potential limitations under Section 382 of the Internal Revenue Code.
Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a New Director and Chief Executive Officer
Business Wire - Wed Nov 26, 3:15PM CST
Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share. The special cash distribution will be paid to shareholders of record at the close of business on December 2, 2014, the record date, on or about December 23, 2014. The Board has also appointed Jonathan M. Couchman as a Class I director of the Company and as its President and Chief Executive Officer, and the remaining members of the Board have resigned. The Company, under the leadership of Mr. Couchman, will continue its evaluation of strategic alternatives.
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Affymax, Inc. Class Action and Settlement Hearing -- AFFY
GlobeNewswire - Wed Nov 26, 3:59AM CST
TO: ALL PERSONS AND ENTITIES THAT PURCHASED AFFYMAX, INC., ("AFFYMAX"
COMMON STOCK DURING THE PERIOD FROM AUGUST 8, 2012 THROUGH FEBRUARY 22, 2013, BOTH DATES INCLUSIVE (THE "CLASS PERIOD" . Xstelos Announces Intention To Vote Against Affymax's Plan Of Liquidation At September 23, 2014 Special Meeting of Shareholders
PR Newswire - Fri Sep 19, 8:15AM CDT
Xstelos Holdings, Inc. and the members of its Schedule 13D group (collectively, the "Xstelos Group" or "we"
own approximately 5.0% of the outstanding shares of common stock of Affymax, Inc. (OTC: AFFY) ("Affymax" or the "Company" . Today, the Xstelos Group announced its intention to vote its shares against Affymax's proposed plan of liquidation at the September 23, 2014 Special Meeting of Shareholders. Renal Anemia - Pipeline Review, H2 2014 - 22 Companies & 25 Drug Profiles
M2 - Mon Sep 08, 11:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpp5q/renal_anemia) has announced the addition of the "Renal Anemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Renal Anemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Renal Anemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Medgenics Inc. - Amgen Inc. - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - FibroGen, Inc. - Japan Tobacco Inc. - Zydus Cadila Healthcare Limited - Bayer AG - 3SBio Inc. - ProMetic Life Sciences Inc. - JCR Pharmaceuticals Co., Ltd. - CCM Duopharma Biotech Bhd. - Panacea Biotec Limited - Affymax, Inc. - Myungmoon pharmaceutical Co.,Ltd. - Intas Pharmaceuticals Ltd. - Acceleron Pharma, Inc. - Pieris AG - Noxxon Pharma AG - Aprogen, Inc. - Dong-A Socio Group Drug Profiles - peginesatide - darbepoetin alfa - epoetin - epoetin alfa - Peg-EPO - roxadustat - sotatercept - GSK-1278863 - lexaptepid pegol - molidustat - MDGN-201 - PEG-EPO - FG-2216 - PRS-080 - epoetin alfa - JTZ-951 - epoetin alfa - DS-1093 - NuPIAO - PBI-1402 - PBI-4050 - ZP-EPO - darbepoetin alfa - MM-P01-01 - Recombinant Protein for Renal Anemia For more information visit http://www.researchandmarkets.com/research/3x...nal_anemia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
MDGN: 6.47 (+0.37), AMGN: 154.10 (+2.79), GSK: 42.45 (+0.65), XLRN: 30.03 (+0.20)
Affymax Reports Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:05PM CDT
Affymax, Inc. (OTCQB:AFFY) today reported financial results for the second quarter ending June 30, 2014. The net income for the second quarter of 2014 was $7.2 million (or $0.19 per share) compared to net income of $15.4 million (or $0.41 per share) for the second quarter of 2013.
